These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 16644766)

  • 1. Remission in depression: definition and initial treatment approaches.
    Israel JA
    J Psychopharmacol; 2006 May; 20(3 Suppl):5-10. PubMed ID: 16644766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
    Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
    J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Achieving remission and managing relapse in depression.
    Thase ME
    J Clin Psychiatry; 2003; 64 Suppl 18():3-7. PubMed ID: 14700448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.
    Nierenberg AA; DeCecco LM
    J Clin Psychiatry; 2001; 62 Suppl 16():5-9. PubMed ID: 11480882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical, psychosocial, and pharmacoeconomic ramifications of remission.
    Thase ME
    Am J Manag Care; 2001 Sep; 7(11 Suppl):S377-85. PubMed ID: 11570028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
    Amsterdam JD; Bodkin JA
    J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An approach to managing depression. Defining and measuring outcomes.
    Khullar A; McIntyre RS
    Can Fam Physician; 2004 Oct; 50():1374-80. PubMed ID: 15526874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Consensus recommendations for improving adherence, self-management, and outcomes in patients with depression.
    Trivedi MH; Lin EH; Katon WJ
    CNS Spectr; 2007 Aug; 12(8 Suppl 13):1-27. PubMed ID: 17986951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinician perspective on achieving and maintaining remission in depression.
    Kelsey JE
    J Clin Psychiatry; 2001; 62 Suppl 26():16-21. PubMed ID: 11775088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Objective: remission of depression in primary care The Oreon Study.
    Ansseau M; Demyttenaere K; Heyrman J; Migeotte A; Leyman S; Mignon A
    Eur Neuropsychopharmacol; 2009 Mar; 19(3):169-76. PubMed ID: 19144502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The definition and meaning of treatment-resistant depression.
    Sackeim HA
    J Clin Psychiatry; 2001; 62 Suppl 16():10-7. PubMed ID: 11480879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating antidepressant therapies: remission as the optimal outcome.
    Thase ME
    J Clin Psychiatry; 2003; 64 Suppl 13():18-25. PubMed ID: 14552652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy.
    van Calker D; Zobel I; Dykierek P; Deimel CM; Kech S; Lieb K; Berger M; Schramm E
    J Affect Disord; 2009 Apr; 114(1-3):243-53. PubMed ID: 18849079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-resistant depression.
    Little A
    Am Fam Physician; 2009 Jul; 80(2):167-72. PubMed ID: 19621857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the efficacy of antidepressants with psychotherapy.
    Petersen TJ
    J Psychopharmacol; 2006 May; 20(3 Suppl):19-28. PubMed ID: 16644768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K; Andersen HF; Reines EH
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial remission indicates poor functioning and a high level of psychiatric symptoms: a 3-phase 6-year follow-up study on major depression.
    Viinamäki H; Hintikka J; Tolmunen T; Honkalampi K; Haatainen K; Koivumaa-Honkanen H
    Nord J Psychiatry; 2008; 62(6):437-43. PubMed ID: 18836926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-resistant depression: prevalence, risk factors, and treatment strategies.
    Thase ME
    J Clin Psychiatry; 2011 May; 72(5):e18. PubMed ID: 21658343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating major depression: antidepressant algorithms.
    Thase ME
    J Clin Psychiatry; 2009 Dec; 70(12):e46. PubMed ID: 20141703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.